Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with a 7-day half-life, used for chronic weight management and type 2 diabetes. Sold under brand names Ozempic and Wegovy; widely compounded.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with a 7-day half-life, used for chronic weight management and type 2 diabetes. Sold under brand names Ozempic and Wegovy; widely compounded. Mechanism: GLP-1 receptor agonist. Typical route: Subcutaneous injection. FDA status: FDA-approved as Ozempic (2017, T2D) and Wegovy (2021, chronic weight management at BMI ≥30, or ≥27 with comorbidity). Compounded semaglutide is dispensed by state-licensed 503A pharmacies under a valid prescription.
Drug classGLP-1 receptor agonist
Half-life~7 days (weekly dosing)
RouteSubcutaneous injection
Typical maintenance2.4 mg/week
FDA statusApproved (Ozempic, Wegovy)
Compounded availability503A pharmacies, patient-specific; not FDA-approved
Mechanism of action
Semaglutide binds the GLP-1 receptor on pancreatic beta cells, stimulating glucose-dependent insulin release; on hypothalamic neurons, reducing appetite and slowing gastric emptying; and on cardiac tissue, contributing to its observed cardiovascular benefit.
Dosing reference
Standard titration: 0.25 mg/week (weeks 1-4), 0.5 mg/week (weeks 5-8), 1.0 mg/week (weeks 9-12), 1.7 mg/week (weeks 13-16), 2.4 mg/week (maintenance). Compounded formulations may follow the same schedule or use mg/mL concentrations of 2.5, 5, or 10 mg/mL.
Dosing information is provided for educational reference and is not medical advice. Patients should not initiate or modify any peptide regimen without consulting a licensed clinician. See our medical disclaimer.
FDA status & regulatory framework
FDA-approved as Ozempic (2017, T2D) and Wegovy (2021, chronic weight management at BMI ≥30, or ≥27 with comorbidity). Compounded semaglutide is dispensed by state-licensed 503A pharmacies under a valid prescription. The FDA published GLP-1 compounding guidance in April 2026.
$99 on 6 months · $105 on 3 months · $109 month to month. The same price at every dose and no membership fee (nexlife.us plan page, read November 6, 2026).
Included in the price: the medication, medical guidance from NexLife Medical Group, a GLP-1 nutrition plan, a 1:1 call with a certified wellness coach, 24/7 support and free expedited shipping. Lab work is not listed as included.
Pharmacies named on its plan pages:Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA), described as state-licensed 503A compounding pharmacies.
Trade-offs: compounded semaglutide is not FDA-approved and is not Wegovy or Ozempic. Cash pay only (FSA/HSA cards accepted for eligible portions). Cancellations take effect after 30 days, so one more shipment may be charged. A prescription depends on a licensed clinician’s review.
$119 on 6 months · $125 on 3 months · $129 month to month. The same price at every dose and no membership fee (nexlife.us plan page, read November 6, 2026).
Included in the price: the medication, medical guidance from NexLife Medical Group, a GLP-1 nutrition plan, a 1:1 call with a certified wellness coach, 24/7 support and free expedited shipping. Lab work is not listed as included.
Pharmacies named on its plan pages:Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA), described as state-licensed 503A compounding pharmacies.
Trade-offs: compounded tirzepatide is not FDA-approved and is not Zepbound or Mounjaro. Cash pay only (FSA/HSA cards accepted for eligible portions). Cancellations take effect after 30 days, so one more shipment may be charged. A prescription depends on a licensed clinician’s review.
U.S. telehealth providers that work with Semaglutide
Semaglutide is FDA-approved for type 2 diabetes (as Ozempic) and chronic weight management (as Wegovy). It is also widely compounded and prescribed off-label or as an alternative to brand-name versions through telehealth providers.
How much weight do people lose on semaglutide?
In the STEP-1 trial of Wegovy, participants lost an average of 14.9% of body weight at 68 weeks at the 2.4 mg/week maintenance dose. Real-world results vary; the average appears to be 10-15% at one year for adherent patients.
Who is the Editor's Pick for compounded semaglutide?
NexLife is our editor’s pick for compounded semaglutide, scoring 94/100 on our v4.1 methodology. NexLife dispenses through a 503A pharmacy with all 50 states covered.
Wilding JPH, Batterham RL, Calanna S, et al.Once-Weekly Semaglutide in Adults with Overweight or Obesity.N Engl J Med. 2021;384(11):989-1002.PMID: 33567185
Marso SP, Bain SC, Consoli A, et al.Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.N Engl J Med. 2016;375(19):1834-1844.PMID: 27633186
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT).N Engl J Med. 2023;389(24):2221-2232.PMID: 37952131
U.S. Food and Drug Administration.FDA approves new drug treatment for chronic weight management, first since 2014.FDA News Release. June 4, 2021.View source
U.S. Food and Drug Administration.Compounded GLP-1 Drugs Used for Weight Loss: Information for Patients and Health Care Providers.FDA Drug Safety Communication. April 2026.View source
Sources are peer-reviewed where available. PubMed (PMID) links resolve to NCBI's PubMed database. FDA links resolve to the U.S. Food and Drug Administration. Citations were last verified 2026-05-11.